In vitro susceptibility of filamentous fungi to systemically active antifungal agents determined by CLSI M38 broth microdilution methods

Organism	Antifungal agent	Number tested	MIC (mcg/mL)
Organism	Antifungal agent	Number tested	50 percent*	90 percent*
Aspergillus fumigatus	Amphotericin B^¶	1119	0.5	1
	Itraconazole	1119	0.5	1
	Isavuconazole	855	0.5	1
	Posaconazole	1119	0.12	0.5
	Voriconazole	1119	0.25	0.5
	Caspofungin	256	0.03	0.06
Aspergillus flavus	Amphotericin B^¶	89	1	2
	Itraconazole	89	0.5	1
	Isavuconazole	444	0.5	1
	Posaconazole	89	0.25	0.5
	Voriconazole	89	0.5	1
	Caspofungin	30	0.03	0.06
Aspergillus niger	Amphotericin B^¶	101	0.12	1
	Itraconazole	101	1	2
	Isavuconazole	207	1	2
	Posaconazole	101	0.25	0.5
	Voriconazole	101	0.5	2
	Caspofungin	29	0.03	0.06
Aspergillus versicolor	Amphotericin B^¶	20	1	2
	Itraconazole	20	1	2
	Isavuconazole	75	0.25	0.5
	Posaconazole	20	0.5	1
	Voriconazole	20	0.5	1
	Caspofungin	20	0.03	0.12
Aspergillus terreus	Amphotericin B^¶	22	2	2
	Itraconazole	22	0.5	0.5
	Isavuconazole	384	0.5	0.5
	Posaconazole	22	0.25	0.25
	Voriconazole	22	0.25	0.5
	Caspofungin	16	0.03	0.06
Fusarium spp	Amphotericin B^¶	67	8	32
	Itraconazole	67	16	32
	Isavuconazole	20	16	>16
	Posaconazole	67	16	32
	Voriconazole	67	16	32
	Caspofungin	13	>8	>8
Scedosporium apiospermum	Amphotericin B^¶	26	2	8
	Itraconazole	26	1	32
	Isavuconazole	16	4	4
	Posaconazole	26	0.25	1
	Voriconazole	13	0.12	0.25
	Micafungin	36	>16	>16
Lomentospora prolificans	Amphotericin B^¶	80	16	32
	Itraconazole	80	64	64
	Isavuconazole	6	16	-
	Posaconazole	80	16	32
	Voriconazole	55	4	4
	Micafungin	17	>32	>32
Mucorales	Amphotericin B^¶	86	0.25	2
	Itraconazole	86	1	32
	Isavuconazole	45	2	16
	Posaconazole	86	0.5	4
	Voriconazole	86	16	128

CLSI: Clinical and Laboratory Standards Institute; MIC: minimum inhibitory concentration.
* 50 percent and 90 percent; MIC encompassing 50 percent and 90 percent of isolates tested, respectively.
¶ Amphotericin B MICs determined by Etest.

Data from:

Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50:2009.
Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41:3623.
Pfaller MA, Messer SA, Boyken L, et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J Clin Microbiol 2008; 46:2568.
Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008; 21:157.
Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob Agents Chemother 2013; 57:3823.
Guinea J, Pelaez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52: 1396.

Graphic 82439 Version 9.0

خرید پکیج

In vitro susceptibility of filamentous fungi to systemically active antifungal agents determined by CLSI M38 broth microdilution methods